Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

IONTAS, Sanofi ink antibody deal
April 2018
SHARING OPTIONS:

CAMBRIDGE, U.K.—In a new partnership for 2018, IONTAS Ltd. and Sanofi have teamed up for the discovery of antibodies using IONTAS’ proprietary Mammalian Display Technology. The technology enables the development of large libraries of monoclonal cell lines, each of which displays a different IgG-formatted antibody on the cell surface. Novel binders can be identified in the libraries using fluorescence-activated cell sorting based on antigen binding.
 
“Historically the consideration of developability issues have been addressed after selection of drug lead molecules,” Dr. John McCafferty, CEO at IONTAS, commented in a statement. “Our Mammalian Display Platform not only allows direct screening of millions of clones for binding affinity and specificity, but also has the potential for early identification of developability issues such as product precipitation. Such issues can derail product development, resulting in significant losses in time and money.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.